

UNITED STATES PATENT AND TRADEMARK OFFICE

BEFORE THE PATENT TRIAL AND APPEAL BOARD

MYLAN PHARMACEUTICALS INC.,
TEVA PHARMACEUTICALS USA, INC., and AKORN INC.,
Petitioners,

v.

SAINT REGIS MOHAWK TRIBE and ALLERGAN, INC.,
Patent Owners.

Case IPR2016-01130
Patent 8,633,162 B2¹

Before SHERIDAN K. SNEDDEN, TINA E. HULSE, and
CHRISTOPHER G. PAULRAJ, *Administrative Patent Judges*.

SNEDDEN, *Administrative Patent Judge*.

JUDGMENT
Final Written Decision
Determining All Challenged Claims Unpatentable
35 U.S.C. § 318(a)

¹ Cases IPR2017-00583 and IPR2017-00599 have been joined with IPR2016-01130.

ORDERS

Dismissing Petitioner’s Motion to Exclude (Paper 50)
37 C.F.R. § 42.64(c)

Dismissing Patent Owner’s Motion to Exclude (Paper 43)
37 C.F.R. § 42.64(c)

I. INTRODUCTION

This Final Written Decision is issued pursuant to 35 U.S.C. § 318(a) and 37 C.F.R. § 42.73. Mylan Pharmaceuticals Inc., Teva Pharmaceuticals USA, Inc., and Akorn Inc. (collectively, “Petitioner”) bears the burden of proving unpatentability of the challenged claims, and that burden of persuasion never shifts to Patent Owner. *Dynamic Drinkware, LLC v. Nat’l Graphics, Inc.*, 800 F.3d 1375, 1378 (Fed. Cir. 2015). To prevail, Petitioner must prove unpatentability by a preponderance of the evidence. 35 U.S.C. § 316(e); 37 C.F.R. § 42.1(d).

For the reasons that follow, we determine that Petitioner has shown, by a preponderance of the evidence, that claims 1–24 of U.S. Patent No. 8,633,162 B2 (Ex. 1001, “the ’162 patent”) are unpatentable.

A. Procedural History

Petitioner filed a Petition to institute an *inter partes* review of claims 1–24 of the ’162 patent. Paper 3 (“Pet.”). Allergan, Inc. (“Patent Owner”) filed a Patent Owner Preliminary Response. Paper 7. Upon consideration of the Petition and Preliminary Response, we instituted an *inter partes* review of claims 1–24 of the ’162 patent on each ground of unpatentability set forth in the Petition, which are as follows:

Ground	Reference[s]	Basis	Claims Challenged
1	Ding '979 ² and Sall ³	§ 103(a)	1–10, 12–14, 16–20, and 22–24
2	Ding '979, Sall, and Acheampong ⁴	§ 103(a)	11 and 21
3	Ding '979, Sall, and Glonek ⁵	§ 103(a)	15

Paper 8 (“Decision on Institution” or “Dec.”).

Subsequently, Patent Owner filed a Patent Owner Response (Paper 16; “PO Resp.”), Petitioner filed a Reply (Paper 34; “Reply”), and Patent Owner filed a Sur-Reply (Paper 42; “Sur-Reply”).⁶

Teva Pharmaceuticals USA, Inc. (“Teva”) and Akorn, Inc. (“Akorn”) each filed Petitions requesting an *inter partes* review of claims 1–24 of the

² Ding et al., US 5,474,979, issued December 12, 1995 (Ex. 1006, “Ding ’979”).

³ Kenneth Sall et al., *Two Multicenter, Randomized Studies of the Efficacy and Safety of Cyclosporine Ophthalmic Emulsion in Moderate to Severe Dry Eye Disease*, 107 OPTHALMOLOGY 631–639 (2000) (Ex. 1007, “Sall”).

⁴ Acheampong et al., *Cyclosporine Distribution into the Conjunctiva, Cornea, Lacrimal Gland, and Systemic Blood Following Topical Dosing of Cyclosporine to Rabbit, Dog, and Human Eyes*, LACRIMAL GLAND, TEAR FILM, AND DRY EYE SYNDROMES 2: BASIC SCIENCE AND CLINICAL RELEVANCE 1001–04 (David A. Sullivan et al. eds., 1998) (Ex. 1008, “Acheampong”).

⁵ Glonek et al., US 5,578,586, issued Nov. 26, 1996 (Ex. 1009, “Glonek”).

⁶ On September 8, 2017, the Saint Regis Mohawk Tribe (the “Tribe”) entered an appearance as the purported Patent Owner. Paper 63. We denied the Tribe’s Motion to Terminate on sovereign immunity grounds and Allergan’s Motion to Withdraw. Paper 127; Paper 129.

IPR2016-01130
Patent 8,633,162 B2

'162 patent in cases IPR2017-00583 and IPR2017-00599, respectfully. IPR2017-00583, Paper 4; IPR2017-00599, Paper 2. Teva and Akorn each filed a motion to join their respective cases with this case. IPR2017-00583, Paper 3; IPR2017-00599, Paper 3. We granted Teva and Akorn's Petitions and each of their motions for joinder. IPR2017-00583, Paper 9; IPR2017-00599, Paper 9.

Per the parties' request, an oral hearing was not held for this proceeding. Paper 150.

B. Related Proceedings

In addition to this proceeding challenging the '162 patent, Petitioner has sought *inter partes* review of all claims of U.S. Patent No. 8,685,930 B2 ("the '930 patent") in IPR2016-00127; U.S. Patent No. 8,629,111 B2 ("the '111 patent") in IPR2016-01128; U.S. Patent No. 8,642,556 B2 ("the '556 patent") in IPR2016-01129; U.S. Patent No. 8,648,048 B2 ("the '048 patent") in IPR2016-01131; and U.S. Patent No. 9,248,191 B2 ("the '191 patent") in IPR2016-01132 (collectively, "the Challenged Patents").

Four of the six Challenged Patents—the '111, '048, '930, and '191 patents—were also at issue in *Allergan, Inc. v. Teva Pharmaceuticals USA, Inc.*, No. 2:15-cv-01455 (E.D. Tex.) ("*Allergan v. Teva*"). The dispute in *Allergan v. Teva* was a "Hatch-Waxman Act case relate[d] to a condition known as 'dry eye' and a pharmaceutical product known as 'Restasis' that is intended to address that condition." Ex. 1164, 1. "Restasis is an emulsion consisting of various components, including the active ingredient cyclosporin A, an immunosuppressant, which is dissolved in castor oil, a fatty acid glyceride." *Id.* The product Restasis is protected by the

Challenged Patents and each of the Challenged Patents is listed in the FDA's Orange Book as patents that claim Restasis, "with respect to which a claim of patent infringement could reasonably be asserted."⁷ *Id.* at 1, 27–29 (citing 21 U.S.C. § 355(b)(1), (c)(2)).

In *Allergan v. Teva*, the district court found thirteen representative claims from those four Challenged Patents invalid as obvious. Ex. 1164. The court explained that its obviousness analysis served to invalidate all claims of those four patents. *Id.* at 32–108. The Federal Circuit affirmed the district court's decision by Rule 36 judgment. *Allergan, Inc. v. Teva Pharms. USA, Inc.*, 742 F. App'x 511 (Mem.) (Fed. Cir. Nov. 13, 2018) (Ex. 1172). Patent Owner's petition for a writ of certiorari was denied. *Allergan, Inc. v. Teva Pharms. USA, Inc.*, 139 S. Ct. 2674 (Mem.) (2019).

During the district court litigation, Patent Owner agreed to treat the thirteen litigated claims as representative of all claims of the Challenged Patents and states that "judgment as to those thirteen claims can be properly applied to all claims of those four patents." PO Supp. Br. 9. With the Federal Circuit's affirmance and the Supreme Court's denial of review, the district court's judgment invalidating all claims of the '111, '048, '930, '191 patents is now final.

In light of the parallel proceeding and the finding of obviousness of the representative claims, we authorized supplemental briefing on the impact of the Federal Circuit's Rule 36 affirmance on the patentability issues in

⁷ The district court refers to the Challenged Patents as the "Restasis patents." Ex. 1164, 23–24.

Explore Litigation Insights

Docket Alarm provides insights to develop a more informed litigation strategy and the peace of mind of knowing you're on top of things.

Real-Time Litigation Alerts



Keep your litigation team up-to-date with **real-time alerts** and advanced team management tools built for the enterprise, all while greatly reducing PACER spend.

Our comprehensive service means we can handle Federal, State, and Administrative courts across the country.

Advanced Docket Research



With over 230 million records, Docket Alarm's cloud-native docket research platform finds what other services can't. Coverage includes Federal, State, plus PTAB, TTAB, ITC and NLRB decisions, all in one place.

Identify arguments that have been successful in the past with full text, pinpoint searching. Link to case law cited within any court document via Fastcase.

Analytics At Your Fingertips



Learn what happened the last time a particular judge, opposing counsel or company faced cases similar to yours.

Advanced out-of-the-box PTAB and TTAB analytics are always at your fingertips.

API

Docket Alarm offers a powerful API (application programming interface) to developers that want to integrate case filings into their apps.

LAW FIRMS

Build custom dashboards for your attorneys and clients with live data direct from the court.

Automate many repetitive legal tasks like conflict checks, document management, and marketing.

FINANCIAL INSTITUTIONS

Litigation and bankruptcy checks for companies and debtors.

E-DISCOVERY AND LEGAL VENDORS

Sync your system to PACER to automate legal marketing.